

MarketsandMarkets Conferences Excited to Partner with Pharmanovia at 4th Annual Orphan Drugs & Rare Diseases Conference

MarketsandMarkets Conferences Excited to Partner with Pharmanovia at the 4th Annual Orphan Drugs and Rare Diseases Conference.

LONDON, UNITED KINGDOM,
September 27, 2023 /
[EINPresswire.com/](https://www.einpresswire.com/) --

[MarketsandMarkets Conferences](#) is delighted to announce its partnership with the global lifecycle management healthcare company, [Pharmanovia](#), for the upcoming 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference. The conference is scheduled to take place on the 9th and 10th of October 2023 at Ibis London Earls Court Hotel & ILEC Conference Centre.



The collaboration between MarketsandMarkets Conferences and Pharmanovia highlights our commitment to fostering connections and facilitating discussions within the pharmaceutical and rare diseases communities. This partnership represents a significant step towards advancing research, development, and solutions for rare diseases, aligning perfectly with the conference's core objectives.

The 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference is expected to bring together industry experts, pharmaceutical leaders, researchers, and stakeholders from around the world. The event will serve as a dynamic platform for sharing knowledge, exploring breakthroughs, and discussing the latest regulatory updates within the orphan drugs and rare diseases sector.

Nivedita Valentine, Global Associate Vice President (AVP) of Product Innovation at Pharmanovia will be attending the [4th annual Orphan and Rare Diseases Conference](#).

Nivedita Valentine, Global AVP of Product Innovation commented "Over 400 million people worldwide have a rare disease, of which- 70-80% are children. Shockingly, only 5% of rare diseases have an approved treatment.

Pharmanovia is committed to improving treatment options for patients globally. We have collaborated with academics, researchers and regulatory authorities across the globe to enhance diagnostics and treatments in orphan conditions including Narcolepsy, Growth Hormone deficiency, and Adrenal insufficiency; with a pipeline in Cardiomyopathy and other rare diseases.

Additionally, Pharmanovia remains actively engaged with IRDiRC , as a part of the Task forces to develop a Drug Repurposing Guidebook and Funding Models designed for use by academic institutions, non-profit organisations, biotech companies, and patient-driven drug developers.

Beyond revitalising and adding value to iconic brands, we aim to leverage our extensive clinical, technical, and commercial platform to address unmet needs (UMN) with novel medicines that complement our existing portfolio across our core therapeutic areas, especially in conditions of high UMN."

As a Visiting Partner, Pharmanovia looks forward to connecting with drug discovery groups, academics, biotech and pharma companies with novel medicinal entities or value-added medicines (phase II/III), for orphan and rare conditions in Cardiovascular, Neurology, endocrinology & bone health or oncology supportive care. If you would like to discuss partnership opportunities, please get in touch at nivedita.valentine@pharmanovia.com

This collaboration represents a significant step forward in the quest to find innovative solutions for rare diseases and underscores the importance of partnerships in driving progress within the pharmaceutical industry."

For more information about the 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference and the partnership with Pharmanovia, please visit or write us at events.marketsandmarkets.com.

About MarketsandMarkets™ Conferences

MarketsandMarkets™ Conferences is a global leader in organizing B2B conferences, summits, and corporate events. Our events provide a platform for industry leaders, decision-makers, and experts to network, share knowledge, and discuss the latest developments in their respective fields. We cover a wide range of industries, including Pharma, Healthcare, Biotechnology, Information Technology, and many more. Our events are attended by excellent delegates from around the world, including Fortune 500 companies, SMEs, startups, and more.

Our conferences are focused on delivering high-quality and informative content, and we bring together leading experts from academia, industry, and government to share insights and best practices, discuss challenges and opportunities, and explore emerging trends and technologies.

At MarketsandMarkets Conferences, we are committed to providing our attendees with the most valuable and informative experience possible. We strive to create an environment that encourages collaboration, innovation, and thought leadership, and we are dedicated to delivering events that exceed our attendees' expectations. Join us at our next conference and discover the latest trends, innovations, and best practices in your industry.

To find out more, visit <https://events.marketsandmarkets.com> or follow us on Twitter, LinkedIn and Facebook.

World Health Organization. Background paper 6.19 Rare Diseases. (2013); Orphanet; RARE Facts. Global Genes .

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.

Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

For more information about Pharmanovia, please visit www.pharmanovia.com

Nayantara Patil
MarketsandMarkets
+91 70305 60809

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/658127183>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.